Lipomas are benign lumps of fat and rank among the most common soft-tissue tumors, while liposarcomas are rare cancers of fat cells that can recur, spread, and threaten life. Both arise from fatty tissue, and both can look deceptively similar on a scan or under a surgeon’s fingers, but they behave in fundamentally different ways. Telling them apart matters enormously for treatment decisions, and the distinction is not always as straightforward as doctors would like.
What Each One Actually Is
A lipoma is a slow-growing, soft, rubbery lump made of mature fat cells enclosed in a thin fibrous capsule. Lipomas account for at least 30 percent of all benign soft-tissue tumors and are overwhelmingly harmless.1Open Exploration Publishing. Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review They do not invade nearby structures, do not metastasize, and rarely cause any symptoms beyond cosmetic concern or occasional pressure on a nerve. Most people who have one never need it removed.
A liposarcoma is a malignant tumor of fat tissue and makes up roughly 20 percent of all soft-tissue sarcomas.2Open Exploration Publishing. Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review Unlike lipomas, liposarcomas carry real potential for local recurrence and, depending on the subtype, metastasis. The World Health Organization recognizes four major subtypes, each with its own genetic fingerprint and clinical behavior: well-differentiated (also called atypical lipomatous tumor), dedifferentiated, myxoid, and pleomorphic.3PubMed. Liposarcomas: diagnostic pitfalls and new insights The well-differentiated form is the most indolent and most common, while dedifferentiated and pleomorphic subtypes are far more aggressive.4PubMed Central. Clinical and Molecular Spectrum of Liposarcoma
How They Feel and Where They Show Up
Most lipomas sit just under the skin, feel soft and doughy, and move easily when you push on them. They tend to be small, often a few centimeters across, and grow slowly over years. People frequently have more than one. Deep lipomas exist too, but they are less common and usually found incidentally on imaging done for something else.
Liposarcomas tend to be deeper. They commonly arise in the thigh, the retroperitoneum (the space behind the abdominal organs), and other deep soft-tissue compartments. They are typically larger at diagnosis. One study comparing atypical lipomatous tumors (the lowest-grade liposarcoma) with ordinary lipomas found the malignant tumors were significantly larger.5BioMed Central / PubMed Central. Differentiation of lipoma and atypical lipomatous tumor by a scoring system: implication of increased vascularity on pathogenesis of liposarcoma A liposarcoma deep in the abdomen can grow very large before causing symptoms, which is why retroperitoneal liposarcomas are often diagnosed late. Any fatty lump that is deep-seated, larger than about 5 centimeters, firm rather than soft, or growing noticeably over weeks rather than years warrants closer investigation.
Imaging Differences on MRI
MRI is the workhorse for evaluating fatty masses. Both lipomas and well-differentiated liposarcomas are predominantly made of fat, so they light up similarly on basic sequences. The challenge is that their appearances can overlap considerably, and distinguishing a benign fatty lump from a low-grade cancer on imaging alone is not always possible.6PubMed. Spectrum of Fat-containing Soft-Tissue Masses at MR Imaging: The Common, the Uncommon, the Characteristic, and the Sometimes Confusing
That said, several MRI features shift the odds strongly toward malignancy. Thick septa (internal walls more than 2 millimeters), globular or nodular non-fatty areas within the mass, and enhancement of those areas after contrast injection all raise suspicion. In one large study, the presence of thick septa increased the likelihood of malignancy by roughly nine-fold, and non-fatty masses within the lesion increased it by about 32-fold. Size above 10 centimeters and a fat fraction below 75 percent were also significant predictors.7PubMed. Imaging of fatty tumors: distinction of lipoma and well-differentiated liposarcoma On the other hand, MRI has been shown to be 100 percent specific for diagnosing a simple lipoma: if the imaging says it is a plain lipoma with no worrisome features, it almost certainly is.8PubMed. Lipomas, lipoma variants, and well-differentiated liposarcomas (atypical lipomas): results of MRI evaluations of 126 consecutive fatty masses
The tricky zone lies with lesions that have some concerning features but are not clearly malignant. A fatty mass with a few thin septa might be a perfectly innocent lipoma or the earliest form of a well-differentiated liposarcoma. Depth, location in the lower extremity, and tumor size above 11 centimeters all add diagnostic weight toward malignancy when combined with the other MRI features.9Scientific Reports. A scoring system combining clinical, radiological, and histopathological examinations for differential diagnosis between lipoma and atypical lipomatous tumor/well-differentiated liposarcoma When imaging alone cannot settle the question, tissue sampling becomes necessary.
The Role of PET Scans
PET/CT, which measures metabolic activity using a radioactive glucose tracer, can help in ambiguous cases. Lipomas have very low metabolic activity, with an average peak tracer uptake (SUVmax) near 1.0, while higher-grade liposarcomas show dramatically higher uptake. In one study, the average SUVmax for dedifferentiated liposarcomas was about 9.3, and for myxoid liposarcomas about 5.2, compared with under 1.0 for lipomas.10Cancer Diagnosis & Prognosis. Differential Diagnosis of Lipomatous Tumors Using 18F-Fluorodeoxygulcose Positron Emission Tomography/Computed Tomography: A Retrospective Observational Study
There is a catch, though. Well-differentiated liposarcomas (atypical lipomatous tumors) can show relatively low uptake too, sometimes barely distinguishable from benign fat. And hibernomas, which are rare but entirely benign brown-fat tumors, can show very high metabolic activity that mimics an aggressive sarcoma.11PubMed Central. 18F-FDG PET/CT imaging features of lipomatous tumors So PET is useful for grading a known liposarcoma or flagging suspicious masses, but it cannot replace biopsy for a definitive diagnosis.
Getting a Definitive Answer Through Biopsy and Molecular Testing
When imaging leaves uncertainty, a core needle biopsy is the next step. Overall, biopsy of fatty tumors carries high accuracy: in one study, the diagnosis at biopsy matched the final surgical diagnosis in 95 percent of cases. For clearly benign lipomas and for higher-grade liposarcomas, the concordance was 100 percent.12PubMed. Image-Guided Core Needle Biopsy of Adipocytic Tumors: Diagnostic Accuracy and Concordance With Final Surgical Pathology The weak spot is, once again, the well-differentiated/atypical lipomatous tumor category, where accuracy dipped to about 81 percent. Four out of 21 tumors initially called well-differentiated at biopsy were upgraded to a higher-grade liposarcoma after full surgical excision. Surgeons and oncologists need to keep this limitation in mind, especially when considering whether to simply observe a fatty mass diagnosed as low-grade at biopsy.
The single most powerful molecular test for separating lipomas from liposarcomas is FISH analysis for MDM2 gene amplification. Lipomas do not have it; well-differentiated and dedifferentiated liposarcomas almost always do. The test achieves 92 to 100 percent specificity and 97 to 100 percent sensitivity for this distinction.13Open Exploration Publishing. Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review In a study of 83 tumors, MDM2 amplification was found only in the liposarcoma cases, appearing in 43 of 51 liposarcomas while being absent in all 25 lipomas tested.14PubMed Central. FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations
The Genetic Split Between the Two
Beyond the diagnostic utility of MDM2, the genetic profiles of lipomas and liposarcomas are quite different, which tells us something about their biology. Ordinary lipomas typically carry simple structural rearrangements involving a gene called HMGA2 on chromosome 12. Well-differentiated liposarcomas, by contrast, have high-level amplification of the MDM2 and CDK4 genes on the same chromosome.15PubMed. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the “missing link” between lipomas and liposarcomas? MDM2 acts as a brake on a key tumor-suppressing protein, and CDK4 drives cell division. When both are overactive, cells grow without the usual checks.
MDM2 amplification is so reliably associated with malignancy and dedifferentiation that researchers have proposed it as one of the clearest markers separating an ordinary lipoma from a well-differentiated liposarcoma at the molecular level.16PubMed. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature This molecular boundary also opens the door to targeted therapy, as described later.
Can a Lipoma Turn Into a Liposarcoma?
This is one of the most common questions patients ask after being told they have a lipoma, and the honest answer is that it happens so rarely that most pathology textbooks treat the two tumors as having separate origins. The prevailing view is that liposarcomas arise de novo, not from pre-existing lipomas. That said, the medical literature does contain a small number of case reports documenting what appears to be malignant transformation. One such report described a man who carried a stable axillary lipoma for 20 years before it rapidly enlarged and was found to be a well-differentiated liposarcoma on excision.17PubMed Central. Liposarcoma in the axilla developed from a longstanding lipoma A veterinary case report recently described a similar phenomenon in a dog, where histology showed a clear transition zone from infiltrative lipoma to dedifferentiated liposarcoma within the same mass.18PubMed. Lingual liposarcoma transitioning from an infiltrative lipoma in a dog
These cases are remarkable precisely because they are so unusual. If you have a stable, superficial lipoma that has not changed in years, the risk of it becoming malignant is vanishingly small. The practical takeaway is not to panic about existing lipomas but to pay attention if one starts growing quickly, becomes painful, or feels firmer than before.
Treatment for Lipomas Versus Liposarcomas
The treatment gap between the two reflects the gap in seriousness. A lipoma that is not bothersome can simply be left alone. If it causes discomfort, cosmetic concern, or diagnostic uncertainty, simple surgical excision is curative, and recurrence after complete removal is rare.
Liposarcoma treatment depends heavily on the subtype and location. Surgery remains the primary approach for all operable disease. For well-differentiated liposarcomas (atypical lipomatous tumors) of the extremities, even marginal excision can work. A systematic review covering nearly 800 patients found local recurrence after marginal excision in about 12 percent of cases and after wide excision in about 3 percent.19PubMed. Surgical management of truncal and extremities atypical lipomatous tumors/well-differentiated liposarcoma: A systematic review of the literature Recurrent tumors could generally be re-excised successfully. In one single-center analysis, local recurrence occurred in about 20 percent of patients regardless of whether margins were microscopically clear or positive, with no significant difference in recurrence-free survival between the two groups.20PubMed. Impact of surgical margins on recurrence after resection of atypical lipomatous tumors: A single-center retrospective analysis This is actually important context: it suggests that for these low-grade tumors, a function-sparing surgery with closer margins may be reasonable rather than an aggressive resection that sacrifices healthy tissue.
Retroperitoneal liposarcomas are a different story. They tend to be large, encase vital organs, and are harder to remove completely, which drives higher recurrence rates.
Radiation and Chemotherapy in Liposarcoma
Well-differentiated liposarcomas are generally insensitive to radiation and chemotherapy, so surgery is the main tool for that subtype.21PubMed Central. Clinical and Molecular Spectrum of Liposarcoma Myxoid liposarcoma, however, stands out as unusually responsive to both. In a nonrandomized trial of reduced-dose preoperative radiation for myxoid liposarcoma, over 90 percent of patients showed extensive pathological response, and local control after limb-sparing surgery was 100 percent.22JAMA Oncology. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial Radiation alone drove a median necrosis rate of roughly 95 percent in myxoid tumors in another study, and adding chemotherapy pushed necrosis rates somewhat higher, though it did not translate into a clear survival benefit.23PubMed Central. Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy
Myxoid liposarcoma is also the most chemotherapy-sensitive subtype among all liposarcomas, making up about 30 percent of cases. Anthracycline-based regimens produce response rates around 40 percent, while trabectedin, a marine-derived drug, achieves responses in about 20 percent of patients and is sometimes used first-line when anthracyclines are not an option.24PubMed. Myxoid Liposarcomas: Systemic Treatment Options For dedifferentiated and pleomorphic subtypes, the evidence for chemotherapy is weaker and outcomes are poorer, which is why researchers are exploring newer approaches.
Survival Differences Among Liposarcoma Subtypes
Subtype is the single biggest determinant of prognosis once a liposarcoma diagnosis is confirmed. Based on a large database analysis, the well-differentiated subtype has five-year survival around 82 percent, myxoid around 79 percent, pleomorphic around 52 percent, and dedifferentiated around 48 percent.25Scientific Reports. Survival and prognostic factors among different types of liposarcomas based on SEER database At 10 years, the survival gap widens further: about 68 percent for well-differentiated versus 31 percent for dedifferentiated. Metastatic disease at presentation reduces survival across all subtypes, and age above 35 is an adverse factor for the well-differentiated and myxoid forms.26PubMed Central. Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis
One reassuring finding is that atypical lipomatous tumors in the extremities, which make up the bulk of well-differentiated cases, almost never metastasize. A UK cohort study found zero metastases and zero disease-specific deaths among 92 patients with extremity atypical lipomatous tumors, and even retroperitoneal well-differentiated tumors showed no metastases in 17 patients, though the recurrence risk in the retroperitoneum remains substantial.27PubMed. Liposarcoma subtype recurrence and survival: A UK regional cohort study When liposarcomas do metastasize, the lungs are by far the most common destination, particularly for pleomorphic and dedifferentiated disease.
Targeted Therapies on the Horizon
Because well-differentiated and dedifferentiated liposarcomas are driven by amplification of specific genes, researchers have been trying to attack those vulnerabilities directly. A phase Ib trial combined siremadlin, which blocks the interaction between MDM2 and the p53 tumor suppressor, with ribociclib, a CDK4/6 inhibitor, in patients with advanced disease who had already progressed on standard therapy. Three patients achieved a partial response and 38 had stable disease, with manageable side effects.28Clinical Cancer Research. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study These are early results, not a breakthrough, but they represent a rational approach: hitting the molecular machinery that separates these cancers from benign lipomas in the first place. Further trials are ongoing.
The Cost of Diagnostic Uncertainty
The overlap between lipomas and liposarcomas on imaging does not just create clinical anxiety; it generates real downstream costs. A study at a specialized sarcoma center tracked incidental fatty masses found on imaging done for other reasons and followed them through the referral and workup process. Cases that ultimately turned out to be benign or of low-risk malignant potential still incurred an average of about €1,857 (roughly $2,155) per case in additional healthcare costs from follow-up imaging, specialist consultations, and biopsies.29PubMed. Incidental imaging findings referred to a specialized sarcoma center: Frequency, determinants, and downstream healthcare costs That is the price of playing it safe with a mass that might look like a lipoma but could be something worse. Most clinicians and patients consider that cost worthwhile, given that missing a liposarcoma carries far graver consequences than over-investigating a lipoma.
Fatty Tumors in Dogs and Cats
If you have a pet, you have probably felt a soft lump under a dog’s skin and been told by a vet that it is “just a lipoma.” Lipomas are extremely common in dogs, especially in middle-aged and older animals. Liposarcomas are rare in pets, just as they are in people. The diagnostic dilemma mirrors the human one: on CT imaging of dogs and cats, malignant fatty tumors are more likely to appear heterogeneous with a dominant soft-tissue component, mineralization, and enlarged nearby lymph nodes, while benign lipomas are homogeneous and well-defined.30Veterinary Radiology & Ultrasound. Comparisons Among Computed Tomographic Features of Adipose Masses in Dogs and Cats The distinction matters in veterinary medicine too, because an infiltrative lipoma that grows into surrounding muscle may need wider surgery, and the rare transformation to liposarcoma has been documented.